News
April 5, 2019

Phenex collaborates with Mathias Heikenwälder ́s research group from DKFZ

The biotech company and Prof. Dr. Heikenwälder see common ground for joint research projects in…
Read More
News
July 10, 2017

Phenex AG announces milestone payment from Janssen for the entry of RORγt inhibitor into Phase I

Phenex drug discovery has now resulted in two clinical stage programs this year through research…
Read More
News
February 23, 2016

Phenex Announces Milestone Payment from Gilead as FXR drug candidate GS-9674 Enters Phase 1 Study

Ludwigshafen, Germany, April 23, 2016 "The revenues from this milestone further secure our strong cash…
Read More
News
December 17, 2015

Phenex AG reaches milestone in collaboration with Janssen

Milestone payment results in further profitability in fiscal year 2015, continuing the trend from 2014…
Read More
News
January 6, 2015

Gilead Sciences announces aquisition of Phenex Pharmaceutical’ development program for non-alcholics steatohepatitis (NASH) and other liver diseases

Foster City, CA and Ludwigshafen/Heidelberg, Germany, January 6, 2015 "This agreement represents a significant milestone…
Read More
News
December 17, 2012

Phenex enters into a Research Collaboration and License Agreement with Janssen for Autoimmune and Chronic Inflammatory Disorders

Phenex will receive an upfront payment and is eligible to receive development-related milestones. Ludwigshafen, Germany,…
Read More
News
October 31, 2012

Phenex reports successful completion of Phase I Studies with FXR-Agonist Px-102 and publishes research progress in two independent papers

On the back of the good scientific news, Phenex raises 5 Mio Euro in its…
Read More
News
September 15, 2011

Phenex initiates Phase I first-in-man study with its clinical development candidate Px-102

The FXR agonist Px-102 might open new avenues for the treatment of Non-Alcoholic Steatohepatitis (NASH)…
Read More
News
July 20, 2011

Phenex wins Prof. Dr. med Dr. rer. nat. Werner Kramer as scientific advisor

Phenex and Prof Kramer will jointly develop Phenex´ FXR agonist Px-102 into a therapy for…
Read More

Contact

Waldhofer Str. 104
69123 Heidelberg, Germany
Phone: +49 6221 65282-0
Fax: +49 6221 65282-10
Dr. Claus Kremoser
Thomas Hoffmann
mailto: info@phenex-pharma.com

About Phenex Pharmaceuticals AG

Phenex is a privately held drug discovery and development company headquartered in Ludwigshafen with a research site in Heidelberg. The biopharmaceutical company can now build on nineteen years of expertise in exploring and defining innovative, potent and selective new drug candidates from small molecules. Phenex´s R&D activities are centered around diseases of liver such as NASH and cancer.